• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Measurement properties of the minimal disease activity criteria for psoriatic arthritis.银屑病关节炎最小疾病活动标准的测量特性。
RMD Open. 2019 Sep 6;5(2):e001002. doi: 10.1136/rmdopen-2019-001002. eCollection 2019.
2
Assessment of Response to Treatment, Remission, and Minimal Disease Activity in Axial Psoriatic Arthritis Treated with Tumor Necrosis Factor Inhibitors.肿瘤坏死因子抑制剂治疗中轴型银屑病关节炎的治疗反应、缓解及最小疾病活动度评估
J Rheumatol. 2016 May;43(5):918-23. doi: 10.3899/jrheum.151404. Epub 2016 Mar 15.
3
Prevalence of minimal disease activity in Australian patients with Psoriatic Arthritis: Assessing the outcome of national funding criteria for biologic disease-modifying antirheumatic drug prescribing.澳大利亚银屑病关节炎患者最小疾病活动度的患病率:评估生物改善病情抗风湿药处方国家资助标准的结果
Int J Rheum Dis. 2019 Feb;22(2):262-268. doi: 10.1111/1756-185X.13441. Epub 2018 Nov 18.
4
Treating Psoriatic Arthritis to Target: Defining the Psoriatic Arthritis Disease Activity Score That Reflects a State of Minimal Disease Activity.针对银屑病关节炎的治疗目标:定义反映疾病低活动状态的银屑病关节炎疾病活动评分。
J Rheumatol. 2020 Mar;47(3):362-368. doi: 10.3899/jrheum.181472. Epub 2019 Jun 15.
5
Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs.接受抗TNF-α药物治疗的银屑病关节炎患者的最小疾病活动度与缓解情况
J Rheumatol. 2016 Feb;43(2):350-5. doi: 10.3899/jrheum.150805. Epub 2015 Dec 15.
6
Comparison of Different Remission and Low Disease Definitions in Psoriatic Arthritis and Evaluation of Their Prognostic Value.比较不同的银屑病关节炎缓解和低疾病定义及其预后价值评估。
J Rheumatol. 2019 Feb;46(2):160-165. doi: 10.3899/jrheum.180249. Epub 2018 Oct 15.
7
Comparison of Composite Indices Tailored for Psoriatic Arthritis Treated with csDMARD and bDMARD: A Cross-sectional Analysis of a Longitudinal Cohort.比较针对接受 csDMARD 和 bDMARD 治疗的银屑病关节炎的综合指标:一项纵向队列的横断面分析。
J Rheumatol. 2017 Aug;44(8):1159-1164. doi: 10.3899/jrheum.170112. Epub 2017 Jun 1.
8
Burden of Psoriatic Arthritis According to Different Definitions of Disease Activity: Comparing Minimal Disease Activity and the Disease Activity Index for Psoriatic Arthritis.根据不同的疾病活动定义评估银屑病关节炎的负担:比较最小疾病活动和银屑病关节炎疾病活动指数。
Arthritis Care Res (Hoboken). 2018 Dec;70(12):1764-1770. doi: 10.1002/acr.23571.
9
Minimal Disease Activity as a Treatment Target in Psoriatic Arthritis: A Review of the Literature.最小疾病活动度作为银屑病关节炎的治疗靶点:文献复习。
J Rheumatol. 2018 Jan;45(1):6-13. doi: 10.3899/jrheum.170449. Epub 2017 Nov 15.
10
Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study.银屑病关节炎的最小疾病活动度及疾病影响:一项西班牙横断面多中心研究
Arthritis Res Ther. 2017 Mar 29;19(1):72. doi: 10.1186/s13075-017-1277-1.

引用本文的文献

1
Impact of Delay of Treatment With Disease-Modifying Antirheumatic Drugs in Psoriatic Arthritis: The CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.改善病情抗风湿药物治疗延迟对银屑病关节炎的影响:CorEvitas银屑病关节炎/脊柱关节炎注册研究
ACR Open Rheumatol. 2025 Jun;7(6):e70019. doi: 10.1002/acr2.70019.
2
Serum IL-23 levels reflect a myeloid inflammatory signature and predict the response to apremilast in patients with psoriatic arthritis.血清白细胞介素-23水平反映了髓系炎症特征,并可预测银屑病关节炎患者对阿普米司特的反应。
Front Immunol. 2024 Dec 4;15:1455134. doi: 10.3389/fimmu.2024.1455134. eCollection 2024.
3
Multi-domain effectiveness of guselkumab evaluated via composite indices through 1 year in patients with PsA and inadequate response to TNFi: post hoc analysis of COSMOS.通过复合指标评估古塞库单抗在银屑病关节炎(PsA)患者中且对肿瘤坏死因子抑制剂(TNFi)反应不足时长达1年的多领域有效性:COSMOS事后分析
Rheumatology (Oxford). 2025 May 1;64(5):2565-2574. doi: 10.1093/rheumatology/keae586.
4
Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trial.氘可来昔替尼,一种选择性TYK2抑制剂,用于治疗银屑病关节炎:2期试验中达到最小疾病活动度标准
Rheumatology (Oxford). 2025 May 1;64(5):2557-2564. doi: 10.1093/rheumatology/keae580.
5
Association Between Achievement of Clinical Disease Control and Improvement in Patient-Reported Outcomes and Quality of Life in Patients With Psoriatic Arthritis in the Phase 3 SELECT-PsA 1 and 2 Randomized Controlled Trials.在3期SELECT-PsA 1和2随机对照试验中,银屑病关节炎患者临床疾病控制的达成与患者报告结局及生活质量改善之间的关联
ACR Open Rheumatol. 2024 Nov;6(11):736-745. doi: 10.1002/acr2.11714. Epub 2024 Aug 1.
6
Management of psoriatic arthritis: a consensus opinion by expert rheumatologists.银屑病关节炎的管理:风湿病专家的共识意见
Front Med (Lausanne). 2023 Nov 30;10:1327931. doi: 10.3389/fmed.2023.1327931. eCollection 2023.
7
Minimal disease activity and remission in patients with psoriatic arthritis with elevated body mass index: an observational cohort study in the Swiss Clinical Quality Management cohort.肥胖指数升高的银屑病关节炎患者的疾病活动度最小化和缓解:瑞士临床质量管理队列中的观察性队列研究。
BMJ Open. 2022 Sep 17;12(9):e061474. doi: 10.1136/bmjopen-2022-061474.
8
Ustekinumab Is Rapid-Acting and Is an Effective Long-Term Treatment for Patients with Active Psoriatic Arthritis: Real-World Evidence from the Non-interventional SUSTAIN Study.优特克单抗起效迅速,是活动性银屑病关节炎患者的有效长期治疗药物:来自非干预性SUSTAIN研究的真实世界证据。
Rheumatol Ther. 2022 Oct;9(5):1435-1450. doi: 10.1007/s40744-022-00484-3. Epub 2022 Sep 6.
9
Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis.古塞单抗为活动性银屑病关节炎患者提供了基于复合指数的持续的、特定域和全面的疗效。
Rheumatology (Oxford). 2023 Feb 1;62(2):606-616. doi: 10.1093/rheumatology/keac375.
10
Consensus statements for evaluation and nonpharmacological Management of Psoriatic Arthritis in UAE.阿联酋中银屑病关节炎的评估和非药物治疗的共识声明。
Int J Rheum Dis. 2022 Jul;25(7):725-732. doi: 10.1111/1756-185X.14357. Epub 2022 Jun 9.

本文引用的文献

1
Comparison of Different Remission and Low Disease Definitions in Psoriatic Arthritis and Evaluation of Their Prognostic Value.比较不同的银屑病关节炎缓解和低疾病定义及其预后价值评估。
J Rheumatol. 2019 Feb;46(2):160-165. doi: 10.3899/jrheum.180249. Epub 2018 Oct 15.
2
Minimal Disease Activity Among Active Psoriatic Arthritis Patients Treated With Secukinumab: 2-Year Results From a Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Study.接受司库奇尤单抗治疗的活动性银屑病关节炎患者的疾病低活动度:一项多中心、随机、双盲、平行分组、安慰剂对照 III 期研究的 2 年结果。
Arthritis Care Res (Hoboken). 2018 Oct;70(10):1529-1535. doi: 10.1002/acr.23537. Epub 2018 Sep 1.
3
Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial.在ADEPT试验中,银屑病关节炎合并活动性皮肤病患者最小疾病活动度的预测及益处
RMD Open. 2017 Jul 18;3(1):e000415. doi: 10.1136/rmdopen-2016-000415. eCollection 2017.
4
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis.银屑病和银屑病关节炎研究与评估小组/风湿病学结局指标共识推荐意见及银屑病关节炎中使用复合指标和治疗目标的研究计划。
Arthritis Rheumatol. 2018 Mar;70(3):345-355. doi: 10.1002/art.40391. Epub 2018 Feb 6.
5
Minimal Disease Activity as a Treatment Target in Psoriatic Arthritis: A Review of the Literature.最小疾病活动度作为银屑病关节炎的治疗靶点:文献复习。
J Rheumatol. 2018 Jan;45(1):6-13. doi: 10.3899/jrheum.170449. Epub 2017 Nov 15.
6
Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort.银屑病关节炎的理想治疗靶点?真实队列中缓解与低疾病活动度状态的比较。
Ann Rheum Dis. 2018 Feb;77(2):251-257. doi: 10.1136/annrheumdis-2017-211998. Epub 2017 Oct 28.
7
Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.托法替布或阿达木单抗与安慰剂治疗银屑病关节炎的比较。
N Engl J Med. 2017 Oct 19;377(16):1537-1550. doi: 10.1056/NEJMoa1615975.
8
Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.托法替布治疗对 TNF 抑制剂应答不足的银屑病关节炎患者。
N Engl J Med. 2017 Oct 19;377(16):1525-1536. doi: 10.1056/NEJMoa1615977.
9
Real-world validation of the minimal disease activity index in psoriatic arthritis: an analysis from a prospective, observational, biological treatment registry.银屑病关节炎最小疾病活动指数的真实世界验证:来自前瞻性、观察性生物治疗登记处的分析
BMJ Open. 2017 Aug 30;7(8):e016619. doi: 10.1136/bmjopen-2017-016619.
10
Clinical Features of Psoriatic Arthritis: a Comprehensive Review of Unmet Clinical Needs.银屑病关节炎的临床特征:未满足的临床需求的综合综述。
Clin Rev Allergy Immunol. 2018 Dec;55(3):271-294. doi: 10.1007/s12016-017-8630-7.

银屑病关节炎最小疾病活动标准的测量特性。

Measurement properties of the minimal disease activity criteria for psoriatic arthritis.

机构信息

Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.

Immunology/Rheumatology, Stanford University, Stanford, California, USA.

出版信息

RMD Open. 2019 Sep 6;5(2):e001002. doi: 10.1136/rmdopen-2019-001002. eCollection 2019.

DOI:10.1136/rmdopen-2019-001002
PMID:31565243
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6744081/
Abstract

OBJECTIVE

To comprehensively assess evidence on the measurement properties of the minimal disease activity (MDA) criteria, a composite measure of the state of disease activity in psoriatic arthritis (PsA).

METHODS

A targeted literature review was conducted to identify studies that informed the validity and/or ability of the MDA to detect change among patients known to have experienced a change in clinical status. The search was conducted using MEDLINE and Embase databases (published as of October 2017). Pertinent articles provided by investigators and identified from select conference proceedings were also evaluated.

RESULTS

A total of 20 publications met the inclusion criteria. The MDA criteria were consistently associated with other indicators of disease activity/severity. The ability of the MDA criteria to detect change was supported in randomised controlled trials (n=10), with a greater percentage of patients randomised to active treatments achieving MDA relative to patients in comparator arms. Long-term observational studies (n=2) provided additional support for the ability of the MDA to detect within-subject change in the real-world settings.

CONCLUSION

Evidence supports the MDA as a valid measure of disease activity in PsA that can detect between-group and within-subject change. The MDA is a comprehensive measure and clinically meaningful endpoint to assess the impact of interventions on PsA disease activity.

摘要

目的

全面评估最小疾病活动(MDA)标准的测量特性,这是一种评估银屑病关节炎(PsA)疾病活动状态的综合指标。

方法

进行了一项有针对性的文献回顾,以确定那些能为 MDA 的有效性和/或检测已知临床状态发生变化的患者变化的能力提供信息的研究。检索使用了 MEDLINE 和 Embase 数据库(截至 2017 年 10 月出版)。还评估了研究人员提供的相关文章和从精选会议论文集中确定的文章。

结果

共有 20 篇出版物符合纳入标准。MDA 标准与其他疾病活动/严重程度的指标始终相关。MDA 标准检测变化的能力在随机对照试验(n=10)中得到支持,与比较组的患者相比,更多随机分配到积极治疗的患者达到 MDA。两项长期观察性研究(n=2)为 MDA 在真实环境中检测个体内变化的能力提供了额外的支持。

结论

证据支持 MDA 作为评估 PsA 疾病活动的有效指标,能够检测组间和个体内的变化。MDA 是一种全面的衡量标准和有临床意义的终点,可用于评估干预措施对 PsA 疾病活动的影响。